Early diagnosis of sepsis is limited by nonspecific clinical signs, slow and often negative blood cultures, and imperfect biomarkers. We evaluated whether plasma metabolomic profiling distinguishes sepsis from nonseptic acute illness better than procalcitonin (PCT), C-reactive protein (CRP) and lactate. Methods: In this prospective diagnostic study at a tertiary teaching hospital in India, 60 adults with sepsis (Sepsis-3) and 60 acutely ill nonseptic controls were enrolled consecutively from the emergency department and intensive care unit. Plasma was profiled by untargeted ultra-performance liquid chromatography–quadrupole time-of-flight mass spectrometry (UPLC–Q-TOF-MS). Analysis used orthogonal partial least-squares discriminant analysis (OPLS-DA), false-discovery-rate (FDR) corrected univariate tests, pathway enrichment, receiver operating characteristic (ROC) analysis, LASSO selection and logistic regression with bootstrap validation. Results: Groups were matched for age, sex, body mass index and comorbidities. Of 3,946 quality-controlled features, 312 differed significantly (FDR q < 0.05; |fold change| ≥ 1.5), and OPLS-DA separated the groups (R²Y = 0.86; Q² = 0.71; permutation P < 0.001). Sepsis showed raised kynurenine, N-formyl-methionine, N-lactoyl-phenylalanine, lactate and acylcarnitines, with lower tryptophan, arginine, citrulline and lysophosphatidylcholines. Tryptophan metabolism and arginine biosynthesis were the most enriched pathways. The kynurenine/tryptophan ratio (AUROC 0.89) outperformed PCT (0.82), CRP (0.76) and lactate (0.73). A five-metabolite panel achieved AUROC 0.93 (sensitivity 88.3%, specificity 86.7%). Adding the panel to conventional markers raised AUROC from 0.85 to 0.96 (DeLong P = 0.002; optimism-corrected 0.94; NRI 0.62). Conclusion: Early sepsis carries a distinct plasma metabolic signature. A five-metabolite panel discriminated sepsis from nonseptic acute illness better than PCT, CRP or lactate and improved a conventional-marker model. External validation with targeted assays is required.
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, operationalised as an acute rise of two or more points in the Sequential Organ Failure Assessment (SOFA) score [1]. It remains one of the most important causes of preventable death worldwide. The Global Burden of Disease analysis estimated 48.9 million incident cases and 11 million sepsis-related deaths in 2017, with the highest burden in low- and middle-income countries [2]. In India, the Indian Intensive Care Case Mix and Practice Patterns Study found that sepsis accounted for a large share of intensive care unit (ICU) admissions and carried substantial mortality [3].
Outcome in sepsis depends heavily on time. In patients with septic shock, each hour of delay before effective antimicrobial therapy was associated with a measurable fall in survival [4]. A large mandated-care programme later confirmed that longer time to completion of the sepsis bundle and to antibiotic administration was associated with higher risk-adjusted in-hospital mortality [5]. Yet recognising sepsis early is difficult. Fever, tachycardia, tachypnoea, leucocytosis and hypotension also occur in trauma, pancreatitis, burns, major surgery and other noninfectious inflammatory states. Elderly and immunocompromised patients may show few typical signs.
Microbiological confirmation does not solve this problem. Blood cultures take 24–72 hours, are negative in many patients with clinically obvious sepsis, and lose sensitivity sharply once antibiotics have been given [6]. Clinicians therefore rely on host-response biomarkers. Procalcitonin (PCT) is the most widely studied, but a meta-analysis of 30 studies reported a pooled area under the receiver operating characteristic curve (AUROC) of only 0.85, concluding that PCT cannot reliably differentiate sepsis from other noninfectious causes of systemic inflammation [7]. C-reactive protein (CRP) is less specific still. More than 250 candidate biomarkers have been studied, yet none has adequate accuracy to be used alone [8]. Serum lactate is valuable for detecting hypoperfusion and grading severity, but it rises in many conditions unrelated to infection and is not a diagnostic test for sepsis [9].
Metabolomics is the comprehensive measurement of low-molecular-weight metabolites in a biological sample [10]. Because the metabolome lies downstream of the genome, transcriptome and proteome, it reflects the integrated biochemical phenotype at the time of sampling. Sepsis disrupts inflammation, mitochondrial function, energy production, amino-acid turnover and lipid metabolism, so it should leave a measurable metabolic footprint. Nuclear magnetic resonance studies first showed that metabolic profiles could separate paediatric septic shock from critically ill controls [11] and adult septic shock from ICU controls [12]. Targeted liquid chromatography–mass spectrometry (LC-MS) studies distinguished sepsis from noninfectious systemic inflammatory response syndrome (SIRS) using acylcarnitines and glycerophospholipids [13], and untargeted LC-MS separated stages of sepsis [14]. Langley and colleagues further showed that metabolites linked to fatty-acid oxidation and energy metabolism differed between sepsis survivors and non-survivors [15].
However, several gaps remain. Many earlier studies compared septic patients with healthy volunteers, which inflates discrimination. Few compared metabolites directly with PCT, CRP and lactate in the same patients, and fewer tested whether metabolites add value to conventional markers. Data from Indian patients, whose case mix, pathogen spectrum and comorbidity profile differ from Western cohorts, are scarce. We therefore aimed to identify plasma metabolites that distinguish Sepsis-3 sepsis from clinically relevant nonseptic acute illness; to compare their diagnostic performance with PCT, CRP and lactate; and to determine whether a metabolite panel improves discrimination when added to conventional markers.
Study design and setting. This prospective observational diagnostic accuracy study was conducted in the Emergency Department, Intensive Care Unit and Department of Biochemistry of Index Medical College and Hospital, India. It is reported according to the STARD 2015 guidelines [16]. The Institutional Ethics Committee approved the protocol, and written informed consent was obtained from each patient or legally authorised representative.
Participants. Consecutive adults (≥ 18 years) presenting with acute illness were screened. The sepsis group comprised patients with suspected or confirmed infection and an acute SOFA increase of ≥ 2 points attributable to infection (Sepsis-3), sampled preferably within 6 hours of presentation [1,17]. The control group comprised acutely ill patients in whom sepsis was excluded after clinical, laboratory, microbiological and imaging evaluation. Exclusion criteria were pregnancy, end-stage renal disease on dialysis, severe chronic hepatic failure, known inherited metabolic disorder, active chemotherapy or profound immunosuppression, haemolysed samples and refusal of consent. Sepsis-induced renal dysfunction was not excluded but adjusted for. With expected sensitivity 0.85, precision ± 0.10 and 95% confidence, 49 cases were required; allowing 10% loss, 60 cases and 60 controls were enrolled.
Clinical and laboratory data. Demographics, comorbidities, vital signs, Glasgow Coma Scale, SOFA score, vasopressor use, mechanical ventilation and source of infection were recorded at enrolment. Total leucocyte count, platelets, CRP, PCT, serum lactate, creatinine, bilirubin and blood glucose were measured by the hospital laboratory using standard methods. Blood cultures were taken before antibiotics where possible. Antibiotic exposure within 72 hours before sampling was recorded.
Sample collection and preparation. Venous blood (5 mL) was collected in EDTA tubes, preferably before antibiotics where this did not delay treatment; sampling and antibiotic times were documented. Plasma was separated by a standardised protocol and stored at −80 °C without repeated freeze–thaw. Plasma was deproteinised with cold methanol containing internal standards [volume ratio and centrifugation settings to be inserted], and the supernatant transferred to LC-MS vials. A pooled quality-control (QC) sample was prepared from aliquots of all specimens [18].
LC-MS analysis. Untargeted profiling used UPLC coupled to Q-TOF mass spectrometry in positive and negative electrospray ionisation modes [column, gradient and source parameters to be inserted]. Samples were run in randomised order, with pooled QC samples and blanks injected throughout the sequence to monitor drift and carry-over.
Data processing and identification. Raw data underwent peak detection, retention-time alignment, deconvolution, adduct filtering, blank subtraction and normalisation using XCMS [19]. Features with relative standard deviation > 30% in pooled QC samples were removed. Metabolites were annotated by accurate mass, isotope pattern and MS/MS spectra against HMDB, confirmed with authentic standards where feasible, and reported by Metabolomics Standards Initiative level [20,21].
Statistical analysis. Continuous variables were compared by Student's t-test or Mann–Whitney U test and categorical variables by chi-square or Fisher's exact test. Univariate metabolite P values were corrected by the Benjamini–Hochberg FDR method [22]. Significant metabolites required FDR q < 0.05 and |fold change| ≥ 1.5. OPLS-DA was validated by cross-validation (R²Y, Q²) and permutation testing; variable importance in projection (VIP) > 1 was considered relevant [23]. Pathway enrichment and topology analysis used MetaboAnalyst with the KEGG Homo sapiens library [24]. Diagnostic performance was assessed by AUROC, with cut-offs chosen by the Youden index. A metabolite panel was selected by LASSO regression [25]. Three logistic models were compared: conventional markers (CRP, PCT, lactate, leucocyte count), the metabolite panel, and both combined, adjusted for age, diabetes, creatinine and prior antibiotics. SOFA was excluded from models to avoid incorporation bias. AUROCs were compared by DeLong's test [26], with net reclassification improvement (NRI) and integrated discrimination improvement (IDI) [27]. Internal validation used 1,000 bootstrap resamples. Analyses used R and SPSS; two-sided P < 0.05 was significant.
One hundred and twenty patients were analysed (60 sepsis, 60 controls). The groups were comparable in age, sex, body mass index and comorbidities (all P > 0.05). Prior antibiotic exposure was borderline more frequent in sepsis (23.3% vs 10.0%; P = 0.05) and was retained as a covariate. Sepsis patients had a median SOFA score of 6 versus 1 in controls, and 36.7% had septic shock (Table 1).
Table 1. Demographic and clinical characteristics of the study population
|
Variable |
Sepsis (n = 60) |
Control (n = 60) |
P value |
|
Age, years, mean ± SD |
56.8 ± 14.2 |
54.1 ± 13.6 |
0.29 |
|
Male sex, n (%) |
36 (60.0) |
33 (55.0) |
0.58 |
|
BMI, kg/m², mean ± SD |
24.6 ± 4.1 |
25.1 ± 3.8 |
0.49 |
|
Diabetes mellitus, n (%) |
22 (36.7) |
18 (30.0) |
0.44 |
|
Hypertension, n (%) |
25 (41.7) |
23 (38.3) |
0.71 |
|
CKD (not on dialysis), n (%) |
7 (11.7) |
5 (8.3) |
0.54 |
|
Antibiotics within 72 h before sampling, n (%) |
14 (23.3) |
6 (10.0) |
0.05 |
|
Mean arterial pressure, mmHg, mean ± SD |
70 ± 13 |
91 ± 12 |
< 0.001 |
|
Total SOFA score, median (IQR) |
6 (4–9) |
1 (0–2) |
< 0.001 |
|
Septic shock (vasopressors), n (%) |
22 (36.7) |
0 |
< 0.001 |
|
28-day mortality, n (%) |
15 (25.0) |
3 (5.0) |
0.002 |
BMI, body mass index; CKD, chronic kidney disease; SOFA, Sequential Organ Failure Assessment.
All conventional markers were higher in sepsis (Table 2). Median PCT was about 20-fold higher (6.4 vs 0.31 ng/mL). However, the interquartile ranges of CRP and lactate overlapped between groups, which limits their use for separating individual patients. Blood cultures were positive in only 43.3% of sepsis patients.
Table 2. Conventional laboratory parameters
|
Parameter |
Sepsis (n = 60) |
Control (n = 60) |
P value |
|
Total leucocyte count, ×10³/µL, mean ± SD |
15.8 ± 6.1 |
10.2 ± 3.4 |
< 0.001 |
|
Platelets, ×10³/µL, mean ± SD |
142 ± 68 |
228 ± 71 |
< 0.001 |
|
CRP, mg/L, median (IQR) |
148 (96–212) |
42 (18–76) |
< 0.001 |
|
Procalcitonin, ng/mL, median (IQR) |
6.4 (2.1–18.5) |
0.31 (0.12–0.68) |
< 0.001 |
|
Serum lactate, mmol/L, median (IQR) |
3.4 (2.3–5.1) |
1.6 (1.1–2.2) |
< 0.001 |
|
Serum creatinine, mg/dL, mean ± SD |
1.8 ± 0.9 |
1.1 ± 0.5 |
< 0.001 |
|
Blood culture positive, n (%) |
26 (43.3) |
0 |
< 0.001 |
Of 4,812 features detected, 3,946 passed QC filtering. In total, 312 features differed significantly between groups (FDR q < 0.05; |fold change| ≥ 1.5), of which 64 were annotated. OPLS-DA showed clear separation (R²Y = 0.86; Q² = 0.71; permutation P < 0.001). Mitochondrial-stress metabolites, lactate, kynurenine and acylcarnitines were increased in sepsis, whereas tryptophan, arginine, citrulline, glutamine and lysophosphatidylcholines (LysoPCs) were decreased (Table 3). The kynurenine/tryptophan ratio was 3.85-fold higher in sepsis.
Table 3. Significantly altered plasma metabolites in sepsis versus controls
|
Metabolite |
Pathway |
Fold change (S/C) |
VIP |
FDR q |
MSI level |
|
N-formyl-methionine |
Mitochondrial |
2.64 ↑ |
2.19 |
< 0.001 |
2 |
|
N-lactoyl-phenylalanine |
Mitochondrial / amino acid |
2.47 ↑ |
2.11 |
< 0.001 |
2 |
|
Lactate |
Glycolysis / energy |
2.31 ↑ |
2.41 |
< 0.001 |
1 |
|
Kynurenine |
Tryptophan–kynurenine |
2.08 ↑ |
2.36 |
< 0.001 |
1 |
|
Hexanoylcarnitine (C6) |
Acylcarnitine / FAO |
1.95 ↑ |
1.87 |
< 0.001 |
2 |
|
Acetylcarnitine (C2) |
Acylcarnitine / FAO |
1.89 ↑ |
1.94 |
< 0.001 |
1 |
|
Octanoylcarnitine (C8) |
Acylcarnitine / FAO |
1.81 ↑ |
1.79 |
0.001 |
2 |
|
Phenylalanine |
Amino acid |
1.72 ↑ |
1.98 |
< 0.001 |
1 |
|
Succinate |
TCA cycle |
1.66 ↑ |
1.52 |
0.004 |
1 |
|
Valine |
BCAA |
0.80 ↓ |
1.12 |
0.034 |
1 |
|
Leucine |
BCAA |
0.78 ↓ |
1.21 |
0.021 |
1 |
|
Sphingomyelin d18:1/16:0 |
Sphingolipid |
0.71 ↓ |
1.41 |
0.009 |
2 |
|
Glutamine |
Amino acid |
0.66 ↓ |
1.62 |
0.002 |
1 |
|
Arginine |
Arginine metabolism |
0.61 ↓ |
1.71 |
< 0.001 |
1 |
|
Citrulline |
Arginine / urea cycle |
0.58 ↓ |
1.76 |
< 0.001 |
1 |
|
Tryptophan |
Tryptophan–kynurenine |
0.54 ↓ |
2.28 |
< 0.001 |
1 |
|
LysoPC(18:2) |
Glycerophospholipid |
0.52 ↓ |
1.84 |
< 0.001 |
2 |
|
LysoPC(16:0) |
Glycerophospholipid |
0.49 ↓ |
1.95 |
< 0.001 |
2 |
S/C, sepsis/control median ratio; VIP, variable importance in projection (OPLS-DA); FAO, fatty-acid oxidation; BCAA, branched-chain amino acid; MSI level 1, confirmed with reference standard; level 2, putative (MS/MS library match).
Seven KEGG pathways remained significant after FDR correction (Table 4). Tryptophan metabolism and arginine biosynthesis were the most strongly enriched, followed by aromatic amino-acid biosynthesis, fatty-acid degradation, glycerophospholipid metabolism, the TCA cycle and pyruvate metabolism.
Table 4. Metabolic pathway enrichment analysis
|
Pathway (KEGG) |
Hits / total |
Raw P |
FDR |
Impact |
|
Tryptophan metabolism |
6 / 41 |
1.2 × 10⁻⁵ |
0.001 |
0.42 |
|
Arginine biosynthesis |
4 / 14 |
3.4 × 10⁻⁵ |
0.001 |
0.38 |
|
Phenylalanine, tyrosine and tryptophan biosynthesis |
2 / 4 |
2.1 × 10⁻⁴ |
0.006 |
0.50 |
|
Fatty acid degradation (carnitine shuttle) |
5 / 39 |
4.8 × 10⁻⁴ |
0.010 |
0.29 |
|
Glycerophospholipid metabolism |
5 / 36 |
9.6 × 10⁻⁴ |
0.016 |
0.24 |
|
Citrate (TCA) cycle |
3 / 20 |
2.3 × 10⁻³ |
0.031 |
0.21 |
|
Pyruvate metabolism / glycolysis |
3 / 22 |
3.0 × 10⁻³ |
0.035 |
0.27 |
|
Alanine, aspartate and glutamate metabolism |
3 / 28 |
6.2 × 10⁻³ |
0.063 |
0.18 |
The kynurenine/tryptophan ratio was the best single marker (AUROC 0.89), exceeding PCT (0.82), CRP (0.76) and lactate (0.73). LASSO selected a five-metabolite panel: kynurenine/tryptophan ratio, N-formyl-methionine, LysoPC(16:0), acetylcarnitine and citrulline. This panel achieved an AUROC of 0.93, with sensitivity 88.3% and specificity 86.7% (Table 5).
Table 5. Diagnostic performance of candidate metabolites and conventional biomarkers
|
Marker |
Cut-off |
AUROC (95% CI) |
Sensitivity, % |
Specificity, % |
PPV, % |
NPV, % |
|
Five-metabolite panel |
≥ 0.48 (probability) |
0.93 (0.89–0.97) |
88.3 |
86.7 |
86.9 |
88.1 |
|
Kynurenine/tryptophan ratio |
≥ 0.071 |
0.89 (0.83–0.95) |
85.0 |
81.7 |
82.3 |
84.5 |
|
N-formyl-methionine |
≥ 1.62 (rel. to QC) |
0.86 (0.79–0.92) |
80.0 |
83.3 |
82.8 |
80.6 |
|
LysoPC(16:0) |
≤ 0.68 (rel. to QC) |
0.84 (0.77–0.91) |
78.3 |
80.0 |
79.7 |
78.7 |
|
Procalcitonin |
≥ 0.5 ng/mL |
0.82 (0.74–0.89) |
78.3 |
75.0 |
75.8 |
77.6 |
|
Acetylcarnitine (C2) |
≥ 1.41 (rel. to QC) |
0.81 (0.73–0.88) |
75.0 |
78.3 |
77.6 |
75.8 |
|
Citrulline |
≤ 0.74 (rel. to QC) |
0.79 (0.71–0.87) |
73.3 |
76.7 |
75.9 |
74.2 |
|
CRP |
≥ 100 mg/L |
0.76 (0.68–0.84) |
71.7 |
70.0 |
70.5 |
71.2 |
|
Serum lactate |
≥ 2.0 mmol/L |
0.73 (0.64–0.82) |
70.0 |
68.3 |
68.9 |
69.5 |
Metabolite cut-offs chosen by Youden index. PPV and NPV calculated at the study prevalence of 50%.
The combined model gave the best discrimination (Table 6). Its AUROC of 0.96 was significantly higher than that of the conventional-marker model (0.85; DeLong P = 0.002) and the metabolite-only model (0.93; P = 0.048). After bootstrap optimism correction the combined AUROC remained 0.94. Calibration was good for all models, and the combined model correctly reclassified a substantial proportion of patients (NRI 0.62).
Table 6. Comparison of diagnostic models (logistic regression, internally validated)
|
Measure |
Model 1: conventional |
Model 2: metabolite panel |
Model 3: combined |
|
Variables |
CRP, PCT, lactate, TLC |
Five-metabolite panel |
Model 1 + Model 2 |
|
AUROC (95% CI) |
0.85 (0.78–0.91) |
0.93 (0.89–0.97) |
0.96 (0.93–0.99) |
|
Optimism-corrected AUROC |
0.83 |
0.90 |
0.94 |
|
Sensitivity, % |
76.7 |
88.3 |
91.7 |
|
Specificity, % |
80.0 |
86.7 |
90.0 |
|
Brier score |
0.14 |
0.09 |
0.07 |
|
Hosmer–Lemeshow P |
0.42 |
0.58 |
0.66 |
|
DeLong P vs Model 1 |
— |
0.031 |
0.002 |
|
NRI vs Model 1 (95% CI) |
— |
0.48 (0.14–0.82) |
0.62 (0.29–0.95) |
|
IDI vs Model 1 |
— |
0.13 |
0.18 |
Models adjusted for age, diabetes, creatinine and prior antibiotics. SOFA excluded to avoid incorporation bias. TLC, total leucocyte count; NRI, net reclassification improvement; IDI, integrated discrimination improvement.
In this prospective study of 120 acutely ill adults, early sepsis showed a distinct plasma metabolic signature. A five-metabolite panel separated sepsis from nonseptic acute illness with an AUROC of 0.93, compared with 0.82 for PCT, and adding it to conventional markers raised the AUROC from 0.85 to 0.96. The signature combined five biological processes: tryptophan catabolism, arginine–citrulline depletion, acylcarnitine accumulation, LysoPC loss and mitochondrial stress.
The choice of comparator matters. Many earlier metabolomic studies compared septic patients with healthy volunteers, which exaggerates discrimination. Mickiewicz et al. reported near-perfect separation of paediatric septic shock from healthy children, but performance fell when critically ill SIRS controls were used [11]. By enrolling acutely ill controls matched for age and comorbidity, our study tested the question clinicians face at the bedside. Even so, the panel outperformed PCT, whose limited accuracy for this distinction has been shown in meta-analysis [7].
The strongest single marker was the kynurenine/tryptophan ratio. Inflammatory cytokines induce indoleamine 2,3-dioxygenase, which converts tryptophan to kynurenine. Kynurenine acts as an endothelium-derived relaxing factor [28] and has been linked to hypotension in human sepsis [29]. Darcy et al. found that the ratio was higher in sepsis than in controls, rose with severity and was associated with impaired immune and microvascular function [30]. Our finding of a 3.85-fold increase is consistent with this mechanism.
Arginine and citrulline were both reduced. Citrulline is synthesised by enterocytes and converted to arginine by the kidney, and reduced citrulline production in sepsis limits de novo arginine and nitric oxide synthesis [31]. Lower citrulline may therefore reflect gut dysfunction as well as increased arginine consumption. LysoPC(16:0) and LysoPC(18:2) were roughly halved. Low LysoPC has been associated with mortality in sepsis [32], and LysoPC administration improved survival in experimental sepsis, suggesting a protective role in bacterial clearance [33]. Acylcarnitine accumulation is consistent with impaired mitochondrial fatty-acid oxidation, and Schmerler et al. similarly found acylcarnitines and glycerophospholipids among the best discriminators of sepsis from SIRS [13]. Langley et al. reported comparable fatty-acid oxidation defects in sepsis non-survivors [15].
N-formyl-methionine and N-lactoyl-phenylalanine were the most increased metabolites. Rogers et al. recently showed that these compounds reflect mitochondrial dysfunction and predict mortality in septic shock [34]. N-formyl peptides are mitochondrial damage-associated molecular patterns that activate neutrophils through formyl peptide receptors [35]. Their rise supports the concept that bioenergetic failure is central to sepsis-induced organ dysfunction [36].
The combined model has practical value. PCT and lactate are already available in many hospitals, and the metabolite panel added significant discrimination to them (NRI 0.62). A targeted assay of five metabolites could, in principle, run on clinical LC-MS/MS platforms already used for steroid and vitamin D testing.
This study has limitations. It is a single-centre discovery cohort of modest size, so overfitting is possible despite bootstrap correction. Several metabolites were identified at MSI level 2 only. Prior antibiotic exposure differed slightly between groups. Predictive values were calculated at 50% prevalence and will be lower in unselected emergency populations. External validation with targeted, absolute quantification is needed before clinical use.
Early sepsis produces a reproducible plasma metabolic signature of tryptophan catabolism, arginine–citrulline depletion, acylcarnitine accumulation, LysoPC loss and mitochondrial stress. A five-metabolite panel distinguished sepsis from nonseptic acute illness more accurately than procalcitonin, CRP or lactate, and improved discrimination when combined with them. These discovery-stage findings support metabolomic profiling as a route to earlier and more specific sepsis diagnosis, pending targeted quantification and multicentre external validation.